Trial Profile

Tagrisso Tablets Clinical Experience Investigation (All Case Investigation)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osimertinib (Primary)
Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions
Sponsors AstraZeneca

Most Recent Events

11 Sep 2020 Results of analysis occurrence of Interstitial Lung Disease during osimertinib use, published in the Journal of Thoracic Oncology
04 Aug 2020 Results assessing adverse drug reactions during real-world osimertinib use were investigated in Japan, published in the Japanese Journal of Clinical Oncology.
08 Oct 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com